September 18, 2025Journal of Psychopharmacology

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment

View Full Paper

Ask AI

Bookmark

Authors

JYJoel YoungDalhousie University RPRichard N. PowellTeradata (United Kingdom)APAnna PowellCampbell University

Discussion

Member takes

Implication

Randomized controlled trial showed solriamfetol improved fatigue and executive function in ME/CFS patients, indicating potential therapeutic benefits.

Key Points

Solriamfetol significantly improved fatigue symptoms at Week 8 compared to placebo, indicating beneficial effects.
The Fatigue Symptom Inventory scores decreased at Week 8 with solriamfetol (p = 0.039), while BRIEF-A scores also showed improvements (p = 0.012).
This phase 4, double-blind, randomized, placebo-controlled trial included 38 adults with myalgic encephalomyelitis/chronic fatigue syndrome.
These findings support solriamfetol's role in managing fatigue symptoms in ME/CFS, suggesting potential for future treatments.

Cite This Study

Young et al. (2025) studied this question.

synapsesocial.com/papers/68d462d231b076d99fa62721 https://doi.org/10.1177/02698811251368371

View Full Paper

Ask AI

Bookmark

Implication

Randomized controlled trial showed solriamfetol improved fatigue and executive function in ME/CFS patients, indicating potential therapeutic benefits.

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider